Edition:
United Kingdom

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

0.32USD
13 Nov 2018
Change (% chg)

-- (--)
Prev Close
$0.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,581
52-wk High
$3.34
52-wk Low
$0.25

Latest Key Developments (Source: Significant Developments)

Apricus Biosciences Q3 Loss Per Share $0.12
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES PROVIDES CORPORATE UPDATE AND THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.12.  Full Article

Apricus Biosciences Entered Into Purchase Agreement With Investor
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES - ON SEPTEMBER 20, CO ENTERED INTO PURCHASE AGREEMENT WITH AN ACCREDITED INVESTOR - SEC FILING.APRICUS BIOSCIENCES - ENTERED INTO SECURITIES PURCHASE AGREEMENT FOR SALE OF 4.6 MILLION SHARES FOR $0.27 PER SHARE.APRICUS BIOSCIENCES - CLOSING OF SALES OF SECURITIES UNDER PURCHASE AGREEMENT IS EXPECTED TO OCCUR ON SEPT 24, 2018.APRICUS - AGREEMENT ALSO FOR SALE OF WARRANTS TO PURCHASE UP TO 3.45 MILLION AT $0.30/SHARE AND WARRANTS TO PURCHASE 2.7 MILLION SHARES AT $0.40/SHARE.  Full Article

Sarissa Capital Management Lp Reports 4.8 Pct Stake In Apricus Biosciences Inc
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Apricus Biosciences Inc ::SARISSA CAPITAL MANAGEMENT LP REPORTS 4.8 PERCENT STAKE IN APRICUS BIOSCIENCES INC AS OF SEPT. 4 - SEC FILING.  Full Article

Apricus Biosciences Announces Merger Agreement With Seelos Therapeutics
Monday, 30 Jul 2018 

July 30 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES, INC. ANNOUNCES MERGER AGREEMENT WITH SEELOS THERAPEUTICS, INC. TO ADVANCE LATE-STAGE PIPELINE OF PRODUCTS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS.APRICUS BIOSCIENCES INC - OWNERSHIP SPLIT OF MERGED COMPANY ANTICIPATED TO BE APPROXIMATELY 86% SEELOS SHAREHOLDERS AND 14% APRICUS SHAREHOLDERS.APRICUS BIOSCIENCES INC - DEAL TERMS INCLUDE CVR PER SHARE TO APRICUS SHAREHOLDERS OF RECORD FOR VITAROS ASSETS AT TIME OF CLOSING.APRICUS BIOSCIENCES INC - NAME OF MERGED COMPANY WILL BE SEELOS THERAPEUTICS.APRICUS BIOSCIENCES - PURSUANT TO MERGER AGREEMENT RAJ MEHRA, CEO OF SEELOS, TO SERVE AS CHAIRMAN, CEO AND PRESIDENT OF MERGED CO.APRICUS BIOSCIENCES - RICHARD PASCOE, CEO OF APRICUS, WILL SERVE ON BOARD OF MERGED CO.APRICUS BIOSCIENCES - PROPOSED MERGER UNANIMOUSLY APPROVED BY BOARD OF EACH CO.  Full Article

Apricus Biosciences Says Entered Subscription Agreement Amendment With Sarissa Capital Domestic Fund
Friday, 22 Jun 2018 

June 22 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES INC - ENTERED SUBSCRIPTION AGREEMENT AMENDMENT WITH SARISSA CAPITAL DOMESTIC FUND & A WARRANT AMENDMENT WITH SARISSA OFFSHORE.APRICUS BIOSCIENCES INC - PURSUANT TO AMENDMENT EXERCISE PRICE OF WARRANTS WAS REDUCED FROM $0.71 TO $0.42 PER SHARE - SEC FILING.  Full Article

Apricus Biosciences Says Co Received A Nasdaq Staff Deficiency Letter
Monday, 16 Apr 2018 

April 16 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES SAYS ON APRIL 10, CO RECEIVED A NASDAQ STAFF DEFICIENCY LETTER - SEC FILING.  Full Article

Sabby Management LLC Reports 7.68 Pct Passive Stake In Apricus Biosciences
Thursday, 29 Mar 2018 

March 29 (Reuters) - Apricus Biosciences Inc ::SABBY MANAGEMENT LLC REPORTS 7.68 PERCENT PASSIVE STAKE IN APRICUS BIOSCIENCES INC AS OF MARCH 28 - SEC FILING.  Full Article

Apricus Biosciences Announces Scheduling Of Vitaros End-Of-Review Meeting With FDA
Monday, 26 Mar 2018 

March 26 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES ANNOUNCES SCHEDULING OF VITAROS™ END-OF-REVIEW MEETING WITH FDA.APRICUS BIOSCIENCES INC - END-OF-REVIEW MEETING WITH U.S. FDA NOW SCHEDULED TO BE HELD ON APRIL 12.APRICUS BIOSCIENCES INC - INTEND TO FURTHER CLARIFY DEFICIENCIES RAISED IN CRL AND INFORMATION THAT MAY BE NEEDED TO RESOLVE SUCH DEFICIENCIE.  Full Article

Apricus Biosciences files for mixed shelf of up to $100 million
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing.  Full Article

Apricus Biosciences reports Q3 loss per share $0.29
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences Inc provides corporate update and third quarter 2017 financial results.Q3 loss per share $0.29.Apricus Biosciences Inc - ‍as of September 30, 2017, company's cash totaled $8.5 million, compared to $2.1 million as of December 31, 2016​.  Full Article